• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

An Armful of Non-Negatives

Let's tick down what hasn't gone wrong -- and what's making this market so resilient.
By JIM CRAMER
Apr 23, 2014 | 01:38 PM EDT
Stocks quotes in this article: T, CMG, YUM, EAT, BBBY, M, GPS, HD, KORS, WMT, TGT, GOOG, VMW, GILD, VRX, AGN, FEYE, MCD, PG, KMB

Sometimes, even on these not-so-vicious down days, it is worth asking: Why isn't the selling more pronounced? How can the Dow Jones Industrial Average have gone from 16,026 a dozen days ago to 16,500 without having taken a pause? How can things be that good?

Isn't that the most salient question?

I think it comes down to a simple truism: The things that are supposed to be go wrong aren't going wrong, or they self-correct -- and we then the stocks just plow forward.

So, in the interest of explaining the streak higher, let's just tick down what hasn't gone wrong and what's adjusting to the new realities behind the scenes -- factors that have made it so the market is just much more resilient than one could expect.

First, we've got a huge non-negative that is causing a giant bid to be put under the market, meaning there are buyers that have no choice but to come in and buy a dip. The secret positive? The Fed and the taper.

For the better part of the last four years investors, and particularly hedge funds, have feared what would happen when the Federal Reserve finished its bond-buying program. But, as my friend and writing colleague Matt Horween pointed out to me this morning, the Fed has been tapering on a methodical basis, and this hasn't caused interest rates to rise one bit. Wasn't that the looming sword of Damocles over the market? Didn't fear of the taper cause a tremendous amount of pressure over and over? Wasn't it used endlessly as a reason not to buy stocks or to sell them on any strength?

Now look at interest rates. They stubbornly refuse to go higher. We are in an incredibly Fed-friendly place: The more tapering it does, perhaps the better, as so many people have refinanced and so many companies have locked in low rates that it is simply time for rates to inch higher, if they can do so at all. You can say the Fed got lucky. Consider that Portugal just sold 10-year sovereign bonds with a rate of 3.5%. Which would you rather have? A 10-year U.S. Treasury yielding 2.7%, or a 3.5% piece of paper from a country that we thought was going to default on its obligations less than three years ago?

Taper's been a victory. It was supposed to be a defeat.

Second: This was the quarter when we were supposed to see more of the same. More cost-cutting and firing. More buying-back of stock to make the numbers. We were not supposed to see revenue growth. That's proving to not be the case. The opposite is playing out. We are seeing very big revenue growth at Boeing (BA), Delta (DAL), United Technologies (UTX), Wells Fargo (WFC), Alcoa (AA) and American Express (AXP), Netflix (NFLX), Coca-Cola (KO) and General Electric (GE). Against those we have very few companies without real good revenue growth. IBM (IBM) didn't have it for certain, but I think it will come in the second half of the year. JPMorgan Chase (JPM) didn't, either, but I think that can correct.

It's ironic, but among some of the stocks that are down, it isn't because of slower revenue. AT&T (T), Chipotle (CMG), Yum! Brands (YUM) and Brinker (EAT) all had very good revenue growth. But their costs weren't in control. AT&T may have to spend too much on its build-out and subsidies. Chipotle, Yum and Brinker all ran into higher food costs -- something I should have known from the Guacapocalypse at Bar San Miguel, the restaurant I co-own in Brooklyn!

Third, there's always some group working that seems to save the day. In a difficult market, we typically get these huge moves against all stocks, and we saw that leading into the bottom on April 11. Since then we have seen some real weakness in certain sectors, but these groups have been spread out and they just haven't sunk the market. Meanwhile, the sectors that should have pulled us down -- the highly valued tech and biotech names -- have been going down but in an orderly way. Of course, if you own them you may not think of it in that manner.

For example, I can't tell you how many times the transports have saved the day, whether it's thanks to the rails or the trucks or, today, the airlines. The oils have been tremendous when it comes to their role in keeping the market higher, as there are some very high-profile large-cap oil companies that just don't quit. Or just when you think that retail's rolling over because of a weak number from Bed Bath & Beyond (BBBY) or Macy's (M) or Gap (GPS), you get an upgrade for Home Depot (HD) or a run-up in Michael Kors (KORS). Oh, and have you noticed Wal-Mart (WMT) and Target (TGT)? They are rocks of Gibraltar, very big rocks of Gibraltar.

You think that the weakest stock in the Dow, Boeing, is going to crush aerospace and you fear it -- and then, bingo, the company reports a terrific number.

At the same time the overvalued stocks -- and I mean the stocks that are being valued at multiples to sales or enterprise values, rather than to earnings -- are rolling over again. Before April 11 it was a negative that they were being crushed. Now, though, as the air is taken out of this bubble with multiple-day declines in software-as-a-service stocks, the most overvalued section of the market, we say: "Phew, this market isn't like 2000, when these stocks caused everything to go down." That's because, by the way, there are two kinds of tech stocks -- the ones that sell at 12x earnings and the ones that sell at 12x sales -- and the latter is not bringing own the former.

Plus, the disappointment in Google (GOOG) last week and in VMware (VMW) today just hasn't caused the collapse we would expect in their cohort, in part because these stocks are viewed as one-off misses. There's just no pin action in whole parts of tech.

The biotech bubble threatened to be a real Hindenberg, but then Gilead (GILD) ended up reporting a great number, even with all of the caveats over the cost of its hepatitis C drug. Valeant (VRX), meanwhile, teamed up with hedge fund manager Bill Ackman to buy Allergan (AGN), making for some interesting speculation for those biotechs that have come down and come down hard. That last one was like an angel reaching out to stem a true blow-off.

Even the initial-public-offering market, which had threatened to pull down the entire edifice with the massive supply, has tapered off. That doesn't mean the most overvalued stocks are out of the insider-selling morass. FireEye (FEYE), the poster boy for insider selling, has been cut in half because of two secondary offerings -- a 14-million-share secondary priced at $82 soon after it spiked to $96, and now a 13-million-share deal that's awaiting pricing somewhere in the $40s. FireEye reinforces the idea that there's no level people at which won't sell these expensive stocks. That's crushing the group today.

Or we get a group that simply doesn't go down purely because it is cheap. The bank stocks, even the bad ones like JPMorgan, either went higher or dropped and then stabilized. These are now value stocks that await higher interest rates to send them up. With the new leadership from Wells Fargo, these shares have been lifting slowly but surely pretty much every day since the bottom. It is amazing that JPMorgan couldn't pull this group down. Again, though, we just aren't witnessing the negative pin action that we had been used to seeing as we headed into this earnings season.

Finally, when we do get mediocre numbers from big-cap stocks such as McDonald's (MCD), Procter & Gamble (PG) or Kimberly-Clark (KMB) or AT&T, the bond-market cushion kicks in because of their terrific dividends. They are much better to own than Treasuries, be they ours or Portugal's.

So the answer is simple to why the market isn't getting killed when it should: Too many bad things aren't happening, and those things that are bad don't spill over to what is good. It seems soporific, but that's how things are playing out, and that amounts to a very benign environment just when you would expect the opposite, especially after a huge run.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Action Alerts PLUS, which Cramer co-manages as a charitable trust, was long BA, IBM, JPM, YUM, GOOG and PG.

TAGS: Investing | U.S. Equity | Financial Services | Healthcare | Consumer Discretionary | Technology | Stocks

More from Healthcare

Emergent BioSolutions Turns Bearish, So Beware

Bruce Kamich
Mar 4, 2021 8:27 AM EST

A break in a key support level could precipitate further declines in the life sciences company's shares.

Centene Charts Remain Weak and Vulnerable

Bruce Kamich
Mar 3, 2021 1:35 PM EST

Let's review the charts and indicators.

Stopped Out on Johnson & Johnson but Willing to Buy it Lower

Bruce Kamich
Mar 3, 2021 12:20 PM EST

Stand aside for now.

Broad Rally, Vaccine Optimism, Johnson & Johnson, GameStop Roars, Trading Nvidia

Stephen Guilfoyle
Feb 25, 2021 7:04 AM EST

The market's catalyst had everything to do with the virus... optimism that humankind might stuff that scourge back into Pandora's box.

Eli Lilly Is Poised for a Pullback Before Renewed Longer-Term Gains

Bruce Kamich
Feb 23, 2021 7:43 AM EST

Let's review the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login